nach oben

PharmacoEconomics

Erschienen in:

01.08.2011 | Practical Application

Cost-of-Illness Studies

A Guide to Critical Evaluation

verfasst von: Allison Larg, John R. Moss

Erschienen in: PharmacoEconomics | Ausgabe 8/2011

Einloggen, um Zugang zu erhalten

Abstract

Cost-of-illness (COI) studies aim to assess the economic burden of health problems on the population overall, and they are conducted for an ever widening range of health conditions and geographical settings. While they attract much interest from public health advocates and healthcare policy makers, inconsistencies in the way in which they are conducted and a lack of transparency in reporting have made interpretation difficult, and have ostensibly limited their usefulness. Yet there is surprisingly little in the literature to assist the non-expert in critically evaluating these studies. This article aims to provide non-expert readers with a straightforward guide to understanding and evaluating traditional COI studies. The intention is to equip a general audience with an understanding of the most important issues that influence the validity of a COI study, and the ability to recognize the most common limitations in such work.

There has been a movement away from using the term ‘indirect’ costs in COI studies, as this term is also commonly used for overhead and other shared costs in patient-level costing of healthcare services within an accounting framework.[2]

It is noted that intangibles are regarded as burdens (on the effects side of the equation) in other aspects of health economic analysis.

To locate such a guide, the clinical literature from PubMed was searched on 8 September 2010 (no date restrictions applied) using the keywords ‘Cost of illness[mh] OR Illness cost*[tiab] OR Costs of disease*[tiab] OR Cost of disease*[tiab] OR Sickness cost*[tiab] OR Cost of sickness[tiab] OR Costs and cost analysis[mh:noexp] OR economic burden[tiab]’ in combination with the terms ‘Guideline[pt] OR Guidance[tiab] OR Guideline*[tiab] OR Guide[tiab] OR Understanding[tiab] OR how to[tiab]’. This wide search of the literature found no general guide to COI studies amongst the 3102 references generated.

However, COI studies should calculate the excess costs that are caused by the disease in question, i.e. the costs for a person with the disease compared with a like person without the disease. The baseline costs required for costeffectiveness analysis of an intervention are the total (not just excess) costs for people with the disease who have not had the intervention, which are then compared with the costs for people with the disease who have the intervention.

This practice has its roots in the theory of human capital developed during the 1960s, and is parallel to valuing physical capital on the basis of its rental income.[51]

Since there is a tendency for certain chronic conditions to occur concurrently, due largely to confounding factors, this is clearly a theoretical proposition only.

A third approach, developed to estimate healthcare costs of smoking in the US[66,67,79] could also be applied for complex health problems. This combination method estimates the per-person mean fraction of healthcare resource use that can be attributed to the disease of interest from person-level data, and then applies these fractions to known expenditure aggregates of relevant components of healthcare service to estimate aggregate attributable costs. Unlike the PAF approach, this does not restrict the analysis to those co-morbidites known to be causally related to the health problem of interest.

Coller et al.[79] found that the higher costs of non-related treatment for smokers than for non-smokers may be responsible for around a third of smoking-attributable healthcare expenditure.

i.e. $PAF = pdj\left[ {{{RRj - 1} \over {RRj}}} \right]$ where pdj is the age-adjusted prevalence of the health problem of interest among the subpopulation who have the attributable condition j, and RRj is the age-adjusted RR of condition j occurring among cases of the health problem of interest compared with a control group.[58,89] A modified formula should also be used for health risks that are measured on a continuous scale.[55]

A possible exception is rare longitudinal person-level studies that track health and resource use for a cohort over time.

Rice DP. Estimating the cost-of-illness. Washington, DC: US Department of Health, Education, and Welfare, Public Health Service, 1966 May

Luce B, Manning W, Siegel J, et al. Estimating costs in costeffectiveness analysis. In: Gold M, Siegel J, Russell L, editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996: 196–213

Shiell A, Gerard K, Donaldson C. Cost of illness studies: no aid to decision making? Health Policy 1987; 8: 317–23CrossRef

Wiseman V, Mooney G. Burden of illness estimates for priority setting: a debate revisited. Health Policy 1998; 43: 243–51PubMedCrossRef

Byford S, Torgerson DJ, Raftery J. Economic note: cost of illness studies. BMJ 2000 May 13; 320 (7245): 1335PubMedCrossRef

Reuter P. What drug policies cost: estimating government drug policy expenditures. Addiction 2006; 101 (3): 315–22PubMedCrossRef

Donaldson C, Narayan K. The cost of diabetes: a useful statistic? Diabetes Care 1998 Aug; 21 (8): 1370–1PubMedCrossRef

Donaldson C, Roux L. Response to Drs Corso, Grosse, and Finkelstein. Obesity 2004 Jul; 12 (7): 1189–90CrossRef

Roux L, Donaldson C. Economics and obesity: costing the problem or evaluating solutions? Obesity 2004 Feb; 12 (2): 173–9CrossRef

10.

Rice DP. Cost of illness studies: what is good about them? Inj Prev 2000; 6: 177–9PubMedCrossRef

11.

Behrens C, Henke K-D. Cost of illness studies: no aid to decision making? Reply. Health Policy 1988; 10: 137–41PubMedCrossRef

12.

Carter R. Macro approach to economic appraisal in the health sector. Aust Econ Rev 1994; 106: 105–12CrossRef

13.

Clabaugh G, Ward MM. Cost-of-illness studies in the United States: a systematic review of methodologies used for direct cost. Value Health 2008; 11 (1): 13–21PubMedCrossRef

14.

Cooper BS, Rice DP. The economic cost of illness revisited. Soc Secur Bull 1976; 39 (2): 21–36PubMed

15.

Hodgson TA. Cost of illness studies: no aid to decision making? Comments on the second opinion by Shiell et al. (Health Policy, 8 (1987) 317–323). Health Policy 1989; 11: 57–60PubMedCrossRef

16.

Koopmanschap MA. Cost-of-illness studies: useful for health policy? Pharmacoeconomics 1998 Aug; 14 (2): 143–8PubMedCrossRef

17.

US Environmental Protection Agency. Cost of illness handbook. In: Agency USEP, editor [online]. Available from URL: http://www.epa.gov/oppt/coi/ [Accessed 2011Apr 18]

18.

Warner KE, Hodgson TA, Carroll CE. Medical costs of smoking in the United States: estimates, their validity, and their implications. Tob Control 1999; 8 (3): 290–300PubMedCrossRef

19.

Rice DP. Cost-of-illness studies: fact or fiction? Lancet 1994; 344 (8936): 1519–20PubMedCrossRef

20.

Finkelstein EA, Corso P. Cost-of-illness analyses for policy making: a cautionary tale of use and misuse. Expert Rev Pharmacoecon Outcomes Res 2003; 3 (4): 367–9PubMedCrossRef

21.

Yabroff KRP, Warren JLP, Banthin JP, et al. Comparison of approaches for estimating prevalence costs of care for cancer patients: what is the impact of data source? Med Care 2009; 47 Suppl.: S64–9CrossRef

22.

Honeycutt AA, Segel JE, Hoerger TJ, et al. Comparing cost-of-illness estimates from alternative approaches: an application to diabetes. Health Serv Res 2009; 44 (1): 303–20PubMedCrossRef

23.

Yabroff KRP, Warren JLP, Schrag DMD, et al. Comparison of approaches for estimating incidence costs of care for colorectal cancer patients. Med Care 2009; 47 Suppl.: S56–63CrossRef

24.

Single E, Collins DJ, Easton B, et al. International guidelines for estimating the costs of substance abuse. Geneva: WHO, 2003

25.

Hodgson TA, Meiners MR. Cost-of-illness methodology: a guide to current practices and procedures. Milbank Mem Fund Q Health Soc 1982; 60 (3): 429–62PubMedCrossRef

26.

Moller L, Matic S. Best practice in estimating the costs of alcohol: recommendations for future studies. Geneva: WHO, 2010

27.

Rice DP, Hodgson TA, Kopstein AN. The economic costs of illness, a replication and update. Health Care Financ Rev 1985; 7: 61–80PubMed

28.

Akobundu E, Jing J, Blatt L, et al. Cost-of-illness studies: a review of current methods. Pharmacoeconomics 2006; 24 (9): 869–90PubMedCrossRef

29.

Rice DP, Hodgson TA, Sinsheimer P, et al. The economic costs of the health effects of smoking, 1984. Milbank Q 1986; 64 (4): 489–547PubMedCrossRef

30.

DeLeire T, Manning W. Labor market costs of illness: prevalence matters. Health Econ 2004; 13 (3): 239–50CrossRef

31.

Collins D, Lapsley H. The social costs of drug abuse in Australia in 1988 and 1992. Commonwealth Department of Human Services and Health, 1996 Feb [online]. Available from URL: http://www.health.gov.au/internet/main/publishing.nsf/Content/6DC5B92CE2170EA3CA256F190004483D/$File/mono30.pdf [Accessed 2011 Apr 18]

32.

Drummond M, O’Brien B, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford University Press, 1997

33.

Finkler SA. The distinction between cost and charges. Ann Intern Med 1982; 96 (1): 102–9PubMed

34.

Philipson T. The welfare loss of disease and theory of taxation. J Health Econ 1995; 14: 387–95PubMedCrossRef

35.

Ried W. Willingness to pay and cost of illness for changes in health capital depreciation. Health Econ 1996; 5: 447–68PubMedCrossRef

36.

Berger MC, Blomquist G, Kenkal D, et al. Valuing changes in health risks: a comparison of alternative measures. South Econ J 1987; 53 (4): 967–84CrossRef

37.

Goddeeris JH. Theoretical considerations on the cost of illness. J Health Econ 1983; 2: 149–59PubMedCrossRef

38.

Marks GC, Coyne T, Pang G. Type 2 diabetes costs in Australia: the potential impact of changes in diet, physical activity and levels of obesity. Canberra (ACT): Commonwealth Department of Health and Aged Care, 2001

39.

Collins DJ, Lapsley H. Counting the cost: estimates of the social costs of drug abuse in Australia in 1998–9. Canberra (ACT): Commonwealth Department of Health and Ageing, 2002

40.

WHO. WHO guide to identifying the economic consequences of disease and injury. Geneva: WHO, 2009

41.

Gold MR. Cost-effectiveness in health and medicine. Oxford: Oxford University Press, 1996

42.

Sindelar J. Social costs of alcohol. J Drug Issues 1998; 28 (3): 763–80

43.

Dagenais S, Caro J, Haldeman S. A systematic review of low back pain cost of illness studies in the United States and internationally. Spine J 2008 Feb; 8 (1): 8–20PubMedCrossRef

44.

Mauskopf J. Prevalence-based economic evaluation. Value Health 1998; 1 (4): 251–9PubMedCrossRef

45.

Fiscella RG, Lee J, Davis EJH, et al. Cost of illness of glaucoma: a critical and systematic review. Pharmacoeconomics 2009; 27 (3): 189–98PubMedCrossRef

46.

Goldstein G, Reznik R, Lapsley H, et al. Costing acute myocardial infarction in New South Wales, Australia, based on incidence rather than prevalence methods. Community Health Stud 1986; 10 (1): 31–8PubMedCrossRef

47.

McGuire A, Irwin DE, Fenn P, et al. The excess cost of acute exacerbations of chronic bronchitis in patients aged 45 and older in England andWales. Value Health 2001; 4 (5): 370–5CrossRef

48.

Golan E, Kuchler F. Willingness to pay for food safety: costs and benefits of accurate measures. Am J Agric Econ 1999; 81 (5): 1185–91CrossRef

49.

Donaldson C, Birch S, Gafni A. The distribution problem in economic evaluation: income and the valuation of costs and consequences of health care programmes. Health Econ 2002; 11 (1): 55–70CrossRef

50.

Mishan EJ. Evaluation of life and limb: a theoretical approach. J Polit Econ 1971; 79 (4): 687–705CrossRef

51.

Mushkin SJ. Health as an investment. J Polit Econ 1962; 70 (5): 129–57CrossRef

52.

Collins DJ, Lapsley H. Estimating the economic costs of drug abuse in Australia. Canberra (ACT): Department of Health and Ageing, 1991

53.

Abelson P, Potter Forbes M, Hall G. The annual cost of foodborne illness in Australia. Canberra (ACT): Australian Government Department of Health and Ageing, 2006 Mar

54.

Brennan A, Purshouse R, Taylor K, et al. Independent review of the effects of alcohol pricing and promotion: part B. Modelling the potential impact of pricing and promotion policies for alcohol in England: results from the Sheffield Alcohol Policy Model Version 2008 (1–1). Sheffield: University of Sheffield, 2008

55.

Murray C, Ezzati M, Lopez A, et al. Comparative quantification of health risks: conceptual framework and methodological issues. In: Ezzati M, Lopez A, Rodgers A, et al., editors. Comparative quantification of health risks: global and regional burden of disease attributable to selected major risk factors. Geneva: WHO, 2004: 1–38

56.

Cabinet Office Strategy Unit. Alcohol misuse: how much does it cost? London: The Stationery Office, 2003

57.

Ezzati M, Lopez A, Rodgers A, et al. Comparative quantification of health risks: global and regional burden of disease attributable to selected major risk factors. Geneva: WHO, 2004

58.

Rockhill B, Newman B, Weinberg C. Use and misuse of population attributable fractions. Am J Public Health 1998 Jan; 88 (1): 15–9PubMedCrossRef

59.

Murray CJL, Lopez AD. On the comparable quantification of health risks: lessons from the global burden of disease study. Epidemiology 1999; 10 (5): 594–605PubMedCrossRef

60.

Bemelmans W, van Baal P, Wendel-Vos W, et al. The costs, effects and cost-effectiveness of counteracting overweight on a population level: a scientific base for policy targets for the Dutch national plan for action. Prev Med 2008; 46 (2): 127–32PubMedCrossRef

61.

Maldonado G, Greenland S. Estimating causal effects. Int J Epidemiol 2002 Apr 1; 31 (2): 422–9PubMedCrossRef

62.

Lee DW, Meyer JW, Clouse J. Implications of controlling for comorbid conditions in cost-of-illness estimates: a case study of osteoarthritis from a managed care system perspective. Value Health 2001; 4 (4): 329–34PubMed

63.

Fishman PAP, Hornbrook MCP. Assigning resources to health care use for health services research: options and consequences. Med Care 2009; 47 Suppl.: S70–5CrossRef

64.

Rappange DR, van Baal PH, van Exel NJ, et al. Unrelated medical costs in life-years gained: should they be included in economic evaluations of healthcare interventions? Pharmacoeconomics 2008; 26 (10): 815–30PubMedCrossRef

65.

van Baal PHM, Polder JJ, de Wit GA, et al. Lifetime medical costs of obesity: prevention no cure for increasing health expenditure. PLoS Med 2008 Feb 1; 5 (2): e29CrossRef

66.

Harrison GW, Feehan JP, Alison CE, et al. Cigarette smoking and the cost of hospital and physician care. Can Public Policy 2003; 29 (1): 1–20CrossRef

67.

Miller VP, Ernst C, Collin F. Smoking-attributable medical care costs in the USA. Soc Sci Med 1999; 48 (3): 375–91PubMedCrossRef

68.

Allison DB, Zannolli R, Narayan KM. The direct health care costs of obesity in the United States. Am J Public Health 1999 Aug 1; 89 (8): 1194–9PubMedCrossRef

69.

Miles S, Fordham R, Mills C, et al. A framework for measuring cots to society of IgE-mediated food allergy. Allergy 2005; 60: 996–1003PubMedCrossRef

70.

Heijink R, Noethen M, Renaud T, et al. Cost of illness: an international comparison Australia, Canada, France, Germany and the Netherlands. Health Policy 2008; 88: 49–61PubMedCrossRef

71.

Molinier L, Combescure C, Chouad C, et al. Cost of lung cancer: a methodological review. Pharmacoeconomics 2006; 24 (7): 651–9PubMedCrossRef

72.

Reuter P. Are calculations of the economic costs of drug abuse either possible or useful? Addiction 1999; 5: 635–8

73.

Kotlarz H, Gunnarsson CL, Fang H, et al. Osteoarthritis and absenteeism costs: evidence from USNational Survey data. J Occup Environ Med 2010; 52 (3): 263–8PubMedCrossRef

74.

Scitovsky AA. Estimating the direct cost of illness. Milbank Mem Fund Q 1982; 60 (3): 463–91CrossRef

75.

Rice D. Estimating the cost of illness. Am J Public Health 1967; 57: 424–40CrossRef

76.

Ettaro L, Songer T, Zhang P, et al. Cost-of-illness studies in diabetesmellitus. Pharmacoeconomics 2004; 22 (3): 149–64PubMedCrossRef

77.

Levine BJ. The other causality question: estimating attributable fractions for obesity as a cause of mortality. Int J Obes 2008; 32 Suppl.: S4–7CrossRef

78.

Greenland S, Robins JM. Conceptual problems in the definition and interpretation of attributable fractions. Am J Epidemiol 1988 Dec 1; 128 (6): 1185–97PubMed

79.

Coller M, Harrison GW, McInnes MM. Evaluating the tobacco settlement damage awards: too much or not enough? Am J Public Health 2002; 92 (6): 984–9PubMedCrossRef

80.

Ohmori-Matsuda K, Kuriyama S, Hozawa A, et al. The joint impact of cardiovascular risk factors upon medical costs. Prev Med 2007; 44 (4): 349–55PubMedCrossRef

81.

Sullivan PW, Ghushchyan V, Wyatt HR, et al. The medical cost of cardiometabolic risk factor clusters in the United States. Obesity 2007 Dec; 15 (12): 3150–8PubMedCrossRef

82.

Weycker D, Nichols GA, O’Keeffe-Rosetti M, et al. Risk factor clustering and cardiovascular disease risk in hypertensive patients. Am J Hypertens 2007; 20 (6): 599–607PubMedCrossRef

83.

Begley CE, Beghi E. The economic cost of epilepsy: a review of the literature. Epilepsia 2002; 43 Suppl.: 3–9PubMedCrossRef

84.

Lipscomb JP, Barnett PGP, Brown MLP, et al. Advancing the science of health care costing. Med Care 2009; 47 Suppl.: S120–6CrossRef

85.

Tarricone R. Cost-of-illness analysis: what room in health economics? Health Policy 2006; 77 (1): 51–63PubMedCrossRef

86.

Kortt MA, Langley PC, Cox ER. A review of cost-ofillness studies on obesity. Clin Ther 1998; 20 (4): 772–9PubMedCrossRef

87.

Flegal KM. Estimating the impact of obesity. Soz Praventivmed 2005; 50 (2): 73–4PubMedCrossRef

88.

Flegal KM, Graubard BI, Williamson DF. Methods of calculating deaths attributable to obesity. Am J Epidemiol 2004 Aug 15; 160 (4): 331–8PubMedCrossRef

89.

Flegal KM, Williamson DF, Pamuk ER, et al. Estimating deaths attributable to obesity in the United States. Am J Public Health 2004; 94 (9): 1486–9PubMedCrossRef

90.

James W, Jackson-Leach R, Ni Mhurchu C, et al. Overweight and obesity (high body mass index). In: Ezzati M, Lopez A, Rodgers A, et al., editors. Comparative quantification of health risks: global and regional burden of disease attributable to selected major risk factors. Geneva: WHO, 2004: 497–596

91.

Hernan MA. Invited commentary: hypothetical interventions to define causal effects. Afterthought or prerequisite? Am J Epidemiol 2005 Oct 1; 162 (7): 618–20PubMed

92.

Levine BJ. What does population attributable fraction mean? Prev Chronic Dis 2007; 40 (1): 1–5

93.

Hernan MA, Taubman SL. Does obesity shorten life? The importance of well-defined interventions to answer causal questions. Int J Obes 2008; 32 (S3): S8–14CrossRef

94.

Coughlin SS, Benichou J, Weed DL. Attributable risk estimation in case-control studies. Epidemiol Rev 1994 Jan 1; 16 (1): 51–64PubMed

95.

Khuwaja A, Khowaja L, Cosgrove P. The economic costs of diabetes in developing countries: some concerns and recommendations. Diabetologia 2010; 53 (2): 389–90PubMedCrossRef

96.

Huang YP. Cost analysis with censored data. Med Care 2009; 47 Suppl.: S115–9CrossRef

97.

Basu AP, Manning WGP. Issues for the next generation of health care cost analyses. Med Care 2009; 47 Suppl.: S109–14CrossRef

98.

Mullahy JP. Econometric modeling of health care costs and expenditures: a survey of analytical issues and related policy considerations. Med Care 2009; 47 Suppl.: S104–8CrossRef

99.

Manning WG. Dealing with skewed data on costs and expenditures. In: Jones AM, editor. Elgar companion to health economics. Cheltenham: Edward Elgar, 2006

100.

Jones A. Applied econometrics for health economists: a practical guide. 2nd ed. Abingdon: Radcliffe Publishing Ltd, 2007

101.

Neftzger AL, Walker S. Measuring productivity loss due to health: a multi-method approach. J Occup Environ Med 2010; 52 (5): 486–94PubMedCrossRef

102.

Schultz AB, Chen C-Y, Edington DW. The cost and impact of health conditions on presenteeism to employers: a review of the literature. Pharmacoeconomics 2009; 27 (5): 365–78PubMedCrossRef

103.

Mattke S, Balakrishnan A, Bergamo G, et al. A review of methods to measure health-related productivity loss. Am J Manag Care 2007 Apr; 13 (4): 211–7PubMed

104.

Ament A, Evers S. Cost of illness studies in health care: a comparison of two cases. Health Policy 1993; 26: 29–42PubMedCrossRef

105.

Glied S. Estimating the indirect cost of illness: an assessment of the forgone earnings approach. Am J Public Health 1996; 86 (12): 1723–8PubMedCrossRef

106.

Donaldson C. The state of the art of costing health care for economic evaluation. Community Health Stud 1990; 14 (4): 341–56PubMedCrossRef

107.

Riley GFM. Administrative and claims records as sources of health care cost data. Med Care 2009; 47 Suppl.: S51–5CrossRef

108.

Lubeck D, Yelin E. A question of value: measuring the impact of chronic disease. Milbank Q 1988; 66 (3): 444–64PubMedCrossRef

109.

Hankivsky O, Friesen J, Varcoe C, et al. Expanding economic costing in health care: values, gender and diversity. Can Public Policy 2004; 30 (3): 257–82CrossRef

110.

Koopmanschap MA, Rutten FFH. A practical guide for calculating indirect costs of disease. Pharmacoeconomics 1996; 10 (5): 460–6PubMedCrossRef

111.

Koopmanschap MA, Rutten FFH, van Ineveld BM, et al. The friction cost method for measuring indirect costs of disease. J Health Econ 1995; 14 (2): 171–89PubMedCrossRef

112.

Koopmanschap MA, Van Exel NJA, Van Den Berg B, et al. An overview of methods and applications to value informal care in economic evaluations of healthcare. Pharmacoeconomics 2008; 26 (4): 269–80PubMedCrossRef

113.

Van Den Berg B, Brouwer W, Van Exel J, et al. Economic valuation of informal care: lessons from the application of the opportunity costs and proxy good methods. Soc Sci Med 2006; 62 (4): 835–45PubMedCrossRef

114.

Van Den Berg B, Brouwer WBF, Koopmanschap MA. Economic valuation of informal care: an overview of methods and applications. Eur J Health Econ 2004; 5 (1): 36–45PubMedCrossRef

115.

O’Shea E. The costs of caring for people with demential and related cognitive impairments. Galway: University of Ireland, 2000

116.

Landefeld JS, Seskin EP. The economic value of life: linking theory to practice. Am J Public Health 1982; 72 (6): 555–66PubMedCrossRef

117.

Johannesson M. Theory and methods of economic evaluation of health care. Dordrecht: Kluwer Academic Publishers, 1996CrossRef

118.

Dolan P, Loomes G, Peasgood T, et al. Estimating the intangible victim costs of violent crime. Br J Criminol 2005; 45: 958–76CrossRef

119.

Pagano E, Brunetti M, Tediosi F, et al. Costs of diabetes: a methodological analysis of the literature. Pharmacoeconomics 1999; 15 (6): 583–95PubMedCrossRef

120.

Begley CE, Annegers JF, Lairson DR, et al. Methodological issues in estimating the cost of epilepsy. Epilepsy Res 1999; 33 (1): 39–55PubMedCrossRef

121.

Calkins JP. Using models that incorporate uncertainty. J Policy Anal Manage 2002; 21 (3): 486–91CrossRef

122.

Moor TJ, Caulkins JP. How cost-of-illness studies can be made more useful for illicit drug policy analysis. Appl Health Econ Health Policy 2006; 5 (2): 75–85CrossRef

123.

Kopp P. Economic costs calculations and drug policy evaluation. Addiction 1999; 5: 641–4

124.

Cartwright WS. Economic costs of drug abuse: financial, cost of illness, and services. J Subst Abuse Treat 2008; 34: 224–33PubMedCrossRef

Titel: Cost-of-Illness Studies
A Guide to Critical Evaluation
verfasst von: Allison Larg
John R. Moss
Publikationsdatum: 01.08.2011
Verlag: Springer International Publishing
Erschienen in: PharmacoEconomics / Ausgabe 8/2011
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI: https://doi.org/10.2165/11588380-000000000-00000

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2011

Challenges in Health State Valuation in Paediatric Economic Evaluation

Estimating the Relationship between Preference-Based Generic Utility Instruments and Disease-Specific Quality-of-Life Measures in Severe Chronic Constipation

Using QALYs in Cancer

Resource Utilization and Cost of Treatment with Anidulafungin or Fluconazole for Candidaemia and Other Forms of Invasive Candidiasis

Cost Estimation of Cardiovascular Disease Events in the US

US FDA Modernization Act, Section 114